A Phase 2 interventional study of HSK7653 10mg Q2W and HSK7653 25mg Q2W in Impaired Glucose Tolerance, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-11-25.
Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Glucose Intolerance with a site in China — 9 open to participants now, 10 under way, none of them phase 3. Glucose Intolerance · China.
Among the 24 studies in Glucose Intolerance with a site in China, this one is the 17th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2021, is one of 2 in phase 2, and was the 11th registered.
793 studies on the registry are indexed under Glucose Intolerance; 115 are open to participants now.
Browse Glucose Intolerance studies →9 of the 24 studies in Glucose Intolerance with a site in China are open now. Recruiting first, the newest first:
Tongji Hospital · Sites in China
Ages 18–70
Huazhong University of Science and Technology · Sites in China
Ages 18–45 · Women only
First Affiliated Hospital Xi'an Jiaotong University · Sites in China
Ages 18–75 · Healthy volunteers
Shanghai General Hospital, China · Sites in China
Ages 20 mo–79 yrs
China-Japan Friendship Hospital · Sites in China
Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 70 Glucose Intolerance studies recruiting now, 14 (20%) set no upper age limit and 51 (73%) stop at 75 or younger; 10 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 99 is above the median of 56 across 661 interventional studies indexed under Glucose Intolerance.
Median enrollment 150 across the 21 interventional studies, 5,000 across the 3 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 24 have an industry lead sponsor. The 10 most frequent:
Haisco Pharmaceutical Group Co., Ltd. is the lead sponsor of 118 studies on the registry; 51 are open to participants now.
Haisco Pharmaceutical Group Co., Ltd. has 1 study filed under Glucose Intolerance — fewer than ten, so there is no comparison to draw.
4 of the studies in Glucose Intolerance with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06958640China-Japan Friendship HospitalDa Qing Offspring Study | 2026-12-31 |
| NCT06553729Huazhong University of Science and TechnologyEffects of Vitamin D and Prebiotic Supplementation on Glucose Control During Pregnancy | 2026-12-31 |
| NCT07718867The University of Hong KongPoint-of-care Capillary HbA1c Testing for Type 2 Diabetes Screening Among At-risk Individuals in Rural Dali, China | 2027-07-31 |
| NCT06964620Tongji HospitalEfficacy and Safety of Sanggua Tablets in the Treatment of Patients With Impaired Glucose Tolerance and Mild Type 2 Diabetes | 2027-11-24 |
Add all 4 to your calendar (.ics) → With an account.
Among the 24 studies in Glucose Intolerance with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is being done to evaluate the efficacy, safety of HSK7653 in chinese participants with impaired glucose tolerance.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: HSK7653 10mg Q2W
Drug: HSK7653 25mg Q2W
Drug: Placebo
HSK7653 5mg (2 tablets) and placebo of HSK7653 25mg (1 tablet) Q2W, oral, Day1 to week12
HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12
Placebo of HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12
Change From Baseline in Plasma Glucose AUC 0-3h for Meal Tolerance Test (MTT) at Week 12
Plasma glucose AUC 0-3 hours for MTT was measured at Baseline (Week 0) and at Week 12. After fasting for ≥8 hours, blood samples for glucose measurement were drawn at 0 minutes (at standard meal loading), 30 minutes, 60 minutes, 90 minutes, 120 minutes, and 180 minutes. At Week 12, participants received study drug or placebo 50 minutes prior to consuming a standard meal.
Time frame: Baseline and Week 12
Change From Baseline in Insulin AUC 0-3h for Meal Tolerance Test (MTT) at Week 12
Time frame: Baseline and Week 12
Change From Baseline in C-peptide AUC 0-3h for Meal Tolerance Test (MTT) at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Fasting Glucose at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Fasting Insulin at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Fasting C-peptide at Week 12
Time frame: Baseline and Week 12
Change From Baseline in HOMA-IS at Week 12
Time frame: Baseline and Week 12
Change From Baseline in HOMA-β at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Plasma Glucose Area Under the Curve 0 to 3 Hours (AUC 0-3 Hrs) for Oral Glucose Tolerance Test (OGTT) at Week 10
Time frame: Baseline and Week 10
Incidence of Treatment-Emergent Adverse Events
Time frame: Baseline and Week 12
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2021 to primary completion in Jun 2022, 14 months.
Of 22 phase 2 interventional studies under Glucose Intolerance, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 99. This study's 14 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HSK7653
Haisco Pharmaceutical Group Co., Ltd. →